The unspliced human immunodeficiency virus type 1 (HIV-1) RNA is both the messenger for Gag and Gag-Pol and the viral genomic RNA (vRNA) that is packaged into the virion. Although Gag alone is sufficient for the incorporation of vRNA into virus particles, Gag-Pol molecules play an important role in vRNA dimerization and virion maturation. Here, a cis model for vRNA packaging was demonstrated, in which nascent Gag-Pol molecules were preferentially co-encapsulated with their cognate RNA used as the template. Genome-incorporation frequencies were evaluated for two distinct HIV-1 proviral clones differing in their ability to respond to nevirapine (NVP) treatment in one round of infection. It was shown that, under NVP selection, there was a twofold-higher incorporation of vRNAs and integration of provirus genome carrying NVP resistance when compared with the wild-type counterpart. Although cis incorporation has been already demonstrated for Gag, the novelty of these findings is that newly acquired resistant mutations in Gag-Pol will select their specific genomic RNA during virus replication, thus rapidly increasing the chance of the emergence of resistant viruses during the course of anti-retroviral treatment.
INTRODUCTION
The process by which two strands of human immunodeficiency virus type 1 (HIV-1) viral genomic RNA (vRNA) are incorporated specifically into an assembling retrovirus particle is known as packaging or encapsulation (Clever et al., 2002) . This process is selective, in that the vRNA constitutes <1 % of the RNA in the infected cell's cytoplasm, yet constitutes most of the RNA inside the virion (Berkowitz et al., 1995; Zhang & Barklis, 1995) . The specificity of packaging is believed to depend largely on direct interactions between the viral Gag polyprotein and a cisacting region located in the 59 leader region of the vRNA known as the packaging signal (y site) (Berkowitz & Goff, 1994; Berkowitz et al., 1996) . These interactions are mediated by the nucleocapsid domain of Gag (Aldovini & Young, 1990; Dorfman et al., 1993; Gorelick et al., 1993; Poon et al., 1996; Provitera et al., 2001) . Furthermore, in order to obtain the interactions required for assembly, Gag molecules first must be concentrated at a cellular site. Detergent-resistant domains at the plasma membrane have been proposed to play an important role in the concentration and alignment of Gag and Gag-Pol molecules (Halwani et al., 2003) . Although Gag alone is sufficient to drive protein multimerization, vRNA incorporation and the assembly of virus particles, incorporation of Gag-Pol is clearly an important event during virus assembly and maturation.
Lentivirus full-length RNA is the template for protein synthesis and is also packaged as the viral genome. Production of infectious particles requires that both vRNA and a number of other viral molecules, including the Gag, GagPol and Env polyproteins, are present concomitantly at budding sites on the plasma membrane. Several lines of evidence suggest that the Gag and Gag-Pol precursors and the vRNA form an intermediate viral-assembly complex in the cytoplasm, which is transported as a unit to the cell membrane for virus assembly and budding (Basyuk et al., 2003; Hill et al., 2001) .
Elucidation of the relationships between viral protein translation and viral RNA packaging is necessary for complete understanding of the retroviral replicative cycle. Gag/ Gag-Pol interactions with vRNA can be explained by two different models: either nascent Gag/Gag-Pol molecules in ribosomes interact specifically with the unspliced vRNA that is being used as the template, which then directs that RNA for encapsidation in cis, or the vRNA interacts with Gag/ Gag-Pol molecules translated by other unspliced RNA in a random fashion in trans. Studies of Gag precursor packaging have shown that Pr55
Gag translation contributes to incorporation of vRNA and suggested that full-length mRNA can be packaged in cis by the same Gag that it synthesizes (Liang et al., 2002; Poon et al., 2002) . In this work, the relationship between translation of the Gag-Pol polyprotein and its association with cognate vRNA during a single cycle of virus replication has been explored. We used an anti-retroviral nevirapine (NVP)-resistance marker within the rt gene region to characterize the relationship between the encapsulation of Gag-Pol molecules and the vRNA used as template during the translation process. Co-transfection experiments with the wild-type genome and its counterpart carrying the NVP-resistant marker in the presence of NVP demonstrated that Gag-Pol molecules carrying the resistance mutation were responsible for a higher incorporation of its cognate vRNA into virus particles, despite an excess of the wild-type counterpart in transfected cells. These results were observed both directly in virus particles and also for the proviral DNA after one round of infection, suggesting that Gag-Pol has a role in selecting its cognate vRNA for packaging. Our data support a cis packaging model in which nascent GagPol molecules are preferentially co-encapsulated with Gag multimers carrying the former cognate vRNA. The model proposed here places together resistant proteins and their viral genomes inside the same virus particle, increasing the chance of survival of viruses exposed to selective external influences, such as anti-retroviral drugs.
METHODS
Vector construction. HIV-1 constructs used in this study were derived from the mutant Z6Dnefgpt infectious clone (Tanuri et al., 2000) . This mutant harbours the xanthine-guanine phosphoribosyl transferase (gpt) selective marker gene from Escherichia coli, in place of the Nef open reading frame. This vector can express the gpt product in infected cells, transducing a positive selective marker for mycophenolic acid (MPA) resistance, a potent inhibitor of de novo purine synthesis (Mulligan & Berg, 1981) . A nucleotide (T) insertion was introduced into the env gene to prevent the expression of the envelope protein; this plasmid was called Z6gptRT wt . Pseudotyped virions were obtained through co-transfections with the plasmid SV-A-MLV-env encoding the murine leukemia virus (MLV) envelope protein (Page et al., 1990) . A mutation that confers high levels of resistance to the reverse transcriptase (RT) inhibitor NVP (Y181C) was introduced into Z6gptRT wt to generate the Z6gptRT Y181C mutant (Richman et al., 1994) . The Z6gptRT Y181C mutant was also modified to include a new BamHI restriction site, which acted as a silent marker to follow recombination events during reverse transcription (Fig. 1) . Each mutation was introduced separately into the respective plasmid by using a QuikChange site-directed mutagenesis kit (Stratagene). The following primers were used: for env gene inactivation, 59-ATTGATGACCTGTAGTTAATGCAGACAATCT-39 (F) and 59-AGATTGTCTGCATTAACTACAGGTCATCAAT-39 (R); for the Y181C mutation, 59-AGAAATAGTTATCTGTCAATACATGGATG-39 (F) and 59-CATCCATGTATTGACAGATAACTATTTCT-39 (R); and for the 59 long terminal repeat (LTR) BamHI site, 59-GTGGTAACTA-GGGATCCCTCAGA-39 (F) and 59-CACCATTGATCCCTAGGGAGT-CT-39 (R). HIV-1-expressing vectors were designed with minimal modifications to avoid changes in RNA and protein export and stability.
Cell culture, transfection experiments and virus production.
COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10 % fetal bovine serum and antibiotics, at 37 uC in a 5 % CO 2 atmosphere. Viruses were produced by transfection of plasmids into COS-7 cells using Lipofectamine (Invitrogen). The two infectious clones, Z6gptRT wt and Z6gptRT Y181C , were either transfected alone or co-transfected in COS-7 cells together with the SV-A-MLV-env expression vector, to produce pseudotyped virions ). Furthermore, a Y181C mutation was introduced in the rt gene to incorporate NVP resistance in the Z6gpt clone and a new BamHI restriction site was inserted into the 59 LTR U5, generating the Z6gptRT Y181C clone. (Fig. 2) . The molecular ratios of Z6gptRT wt and Z6gptRT Y181C for co-transfections varied from 1 : 1 to 5 : 1 in different experiments. COS-7 culture supernatants were harvested 72 h after transfection, centrifuged and filtered through a 0?45 mM pore-size filter. Virus production was quantified by measuring p24 antigen levels in the cell-culture supernatants (Vironostika HIV-1 Antigen; bioMériex Laboratories). Virus aliquots were stored at 270 uC.
Infection and drug selection. COS-7 cells were exposed to different concentrations of NVP (0-50 mM) 4 h prior to infection and during the whole infection procedure to select for resistant viral progeny. Cultures were infected with 15 ng viral p24 antigen during an adsorption period of 4 h at 37 uC, after which supernatants were removed and fresh medium added. Two days after infection, cells were transferred to 100 mm dishes in the presence of MPA medium (DMEM supplemented with 10 % fetal calf serum, 200 mg xanthine ml
21
, 25 mg hypoxanthine ml 21 and 15 mg MPA ml
). Cells were fed every 3-4 days and, after 15-21 days, colonies were transferred individually through cloning cylinders (Fischer) to 24-well plates and expanded in selection medium. Survival of colonies resistant to MPA treatment is a direct measure of the number of infected cells and therefore the number of infectious particles within the virus stocks. To evaluate cell survival after MPA treatment, grown colonies were stained with crystal violet (5 % acetic acid, 25 % methanol, 0?5 % crystal violet) and scored.
HIV genome incorporation in Z6gpt
+ cell clones. Total genomic DNA was extracted from MPA-resistant cell clones by using a Wizard DNA Genomic Extraction kit (Promega). Two different HIV-1 genomic regions were targeted for PCR amplification: the rt gene and the U5 region from the 39 LTR. Amplification of the rt gene was performed as described previously (Caride et al., 2000) . Amplification products were purified by using QIAquick purification columns (Qiagen) and sequenced in an ABI model 3100 automated DNA sequencer (Applied Biosystems) to evaluate the presence of the NVP-resistance marker (Y181C) in the rt gene. The U5 region from the 39 LTR was amplified by using 59-GTCCCGCCAATCTCCGGT-CGCTAA-39 as the forward primer annealing at the 39 end of the gpt gene and 59-GCTAGAGATTTTCCACTCTGACTA-39 as the reverse primer annealing at the 39 end of the HIV-1 genome. Amplification products of the U5 region were submitted to digestion reactions with BamHI (Promega) and separated on a 1?2 % agarose gel. The Z6gptRT wt -derived fragment was visualized as a 702 bp fragment (uncut) and the Z6gptRT Y181C -derived fragment as two fragments (668 and 34 bp) after digestion.
Natural endogenous RT (NERT) reaction. The NERT assay was performed by a modification of the technique of Hooker et al. (2001) . Aliquots of intact virus particles were exposed or not to increasing concentrations of NVP 2 h prior to NERT reactions. After NVP treatment, virus aliquots were incubated with 20 U DNase I (Invitrogen) and 10 mM MgCl 2 for 60 min at 37 uC in a final reaction volume of 25 ml. After incubation, 400 mM dNTPs were added to each tube (except to the negative controls) and further incubated at 37 uC for 2 h. Enzymic activity was terminated by the addition of 37?5 ml stop solution [10 mM Tris/HCl (pH 7?4), 10 mM EDTA, 20 mg sheared salmon sperm DNA ml 21 , 50 mg proteinase K ml 21 ], followed by incubation for 10 min at 37 uC and a further 10 min at 96 uC. The Z6gptRT wt and Z6gptRT Y181C viruses used for NERT reactions encoded HIV-1 wild-type Env proteins. Samples of each stopped reaction mixture were assayed for minusstrand strong-stop DNA (2ssDNA) by quantitative real-time PCR using combinations of the following oligonucleotides and probe: SSF1 (59-GCTAACTAGGGAACCCACTGCTT-39), SSR1 (59-CAACA-GACGGGCACACACTACT-39) and single-stranded DNA probe (59-AGCCTCAATAAAGCTTGCCTTGAGTGCTTC-39). Reaction mixtures (final volume 25 ml) contained 16 Taqman Universal PCR mixture (Applied Biosystems), 0?25 pmol each primer, 0?05 pmol probe and Pseudotyped viruses were used to infect fresh COS-7 cells exposed or not to NVP selection 4 h prior to infection and during the whole infection process. At 48 h post-infection, cells were selected by MPA resistance. After 15-20 days MPA selection, Z6gpt + cell clones were stained and counted or isolated and subsequently expanded to recover genomic DNA from the cells.
4 ml NERT stopped reaction. Amplification was performed with an ABI Prism 7000 sequence detection system (Applied Biosystems). Cycling conditions were as follows: 50 uC for 2 min, 95 uC for 10 min, and 50 cycles of 95 uC for 15 s and 60 uC for 1 min. Realtime PCR standard curves used for the quantification of synthesized 2ssDNA were constructed by using proviral plasmid DNA (Z6gptRT wt ) diluted serially in NERT stop solution.
Direct identification of HIV genome in cell-free virus particles by the NERT reaction. We used the NERT reaction product from virus obtained from 1 : 1 co-transfection (Z6gptRT wt : Z6gptRT Y181C ) to identify the nature of the HIV genome incorporated directly into these virus particles. Intact viruses obtained from 1 : 1 co-transfection were exposed to increasing concentrations of NVP before the NERT reactions, as described above. Products of the NERT reaction were used to amplify the 59 LTR U5 region from the 2ssDNA template. Samples of each stopped reaction mixture were amplified using specific oligonucleotides flanking the BamHI site present on the Z6gptRT Y181C genome: D1 (59-GGTCTCTCTGGTTAGACCA-39) and P2-FAM (59-CTGCTAGAGATTTTTCCACACTGAC-39). The NERT PCR product was resolved in 1 % agarose gel and quantified. Aliquots of 100 ng of each PCR product were digested with 10 U BamHI. The digested fragments were purified and resolved in a 310 ABI automated sequencer (Applied Biosystems). All samples were run with the Prism GeneScan 500 Tamra size standard (Applied Biosystems) to identify the precise length and peak area of BamHIdigested fragments. The peak areas of digested fragments (181 nt of Z6gptRT wt genome and 38 nt of Z6gptRT Y181C genome) were analysed using GENESCAN software (Applied Biosystems). The BamHI digestion fragment patterns of each virus (Z6gptRT wt or Z6gptRT Y181C ) were used as controls for total digestion. The peak area ratios for Z6gptRT Y181C : Z6gptRT wt from NERT reactions were calculated in the presence and absence of NVP.
Statistical analyses. Differences between Z6gptRT wt and Z6gptRT Y181C genome frequencies in Z6gpt + cell clones submitted or not to NVP selection were compared by using x 2 tests. A P value of 0?05 or less was considered statistically significant. Both linear and non-linear regressions between the plots in the graphics were calculated by using SigmaPlot software, version 8.0. In the nonlinear regression, we used the equation of Hill, with four parameters of the sigmoidal function.
RESULTS

Vector construction and analyses
To study the specificity of drug-resistant vRNA incorporation into HIV-1 particles following drug treatment, a genetic system was developed in which two env-negative proviral clones harbouring the gpt gene in place of the viral nef gene and differing only in their ability to respond to NVP treatment were expressed simultaneously in COS-7 cells (Fig. 1) . Therefore, pseudotyped viruses carrying NVP-resistant RT could be selected specifically by NVP treatment during infection of COS-7 cells and single infected-cell colonies isolated by selection with MPA (Fig. 2) .
First, to determine the ability of the Z6gptRT wt and Z6gptRT Y181C viruses to express the gpt marker, cells were infected individually with these viruses and colonies of infected cells were selected as described above. Both infections gave rise to the same number of surviving colonies, indicating that both viruses were able to transduce the gpt selective marker (Table 1) (Fig. 3) . For infections carried out with viruses obtained from 1 : 1 (Z6gptRT wt : Z6gptRT Y181C ) co-transfection, the survival curve demonstrated that concentrations of NVP ranging from 0?1 to 0?5 mM would be sufficient to select only viruses carrying a sufficient number of Y181C mutant RTs to ensure its replication capacity (Fig. 3 ).
Viral RNA incorporation into viable virus particles
We investigated further whether the packaging of vRNA was specific for its cognate Gag-Pol following anti-retroviral treatment. During virus assembly, Gag-Pol molecules could interact specifically with multimeric Gag carrying the former cognate RNA molecule used as template during translation (in cis model) or randomly with multimeric Gag carrying non-cognate vRNA molecules (in trans model). Considering a mixture of equal amounts of the wild-type and the mutant full-length vRNAs within a virus-producer cell, the same proportions of wild-type (Z6gptRT wt ) and resistant (Z6gptRT Y181C ) RT alleles would be expected to be detected within new virions with no NVP treatment in both in cis and in trans models. However, an increased allele frequency of RT Y181C over RT wt genomes under NVP selection would suggest specific (in cis) incorporation of Gag-Pol to the Gag/vRNA complex and an influence of Gag-Pol molecules in vRNA incorporation. On the other hand, the maintenance of equal proportions of RT alleles, despite the presence of selective pressure, would suggest a random profile of interaction between the Gag/vRNA complex and Gag-Pol molecules (in trans model).
Experiments were conducted by infecting COS-7 cells with virus stocks produced from ratios of 1 : 1 and 5 : 1 (Z6gptRT wt : Z6gptRT Y181C ) co-transfections in the presence or absence of NVP. Z6gpt
+ MPA-resistant cell clones were isolated and expanded for proviral DNA analyses of the RT and 39 LTR regions. For all analyses, at least 100 individual samples were obtained. To test for co-transfection efficiency and incorporation of both Z6gptRT wt and Z6gptRT Y181C vRNA into the same virus particle, a mutation was introduced in the 59 LTR U5 region of Z6gptRT Y181C to include a new BamHI restriction site (Fig. 1) . Synthesis of both minus-and plus-strand DNA involves template switching in which the strong-stop DNA is transferred from the original template to a complementary sequence at the 39 end of either the same or a second homologous copy of the RNA template (Gilboa et al., 1979) . Therefore, recombination occurs as a result of RT switching templates between co-packaged RNA molecules during DNA synthesis (Levy et al., 2004) . By using BamHI restriction of proviral DNA, it was possible to characterize, in proviral DNA from transduced cells, a high proportion of recombinant genomes between RT and the 39 LTR regions from infections carried out with or without NVP selection, confirming the presence of both vRNAs in single virus particles. In fact, up to 42 % of integrated genomes originated from recombination in transfection ratios of 1 : 1, regardless of NVP selection. These results demonstrated that both RNAs are typically used during HIV-1 reverse transcription and confirmed equal proportions of the two proviral clones (Z6gptRT wt and Z6gptRT Y181C ) in the same virus particle. In fact, as recombination is very frequent during HIV-1 retrotranscription and, assuming that each virus particle undergoes one recombination event during this process (Zhuang et al., 2002) , we could assume that approximately 40 % of the infectious viruses obtained from 1 : 1 co-transfections were composed of one copy each of the Z6gptRT wt and Z6gptRT Y181C RNA genomes.
As the rt gene carried the selective marker used to target Gag-Pol, we focused further genetic analyses on this region. The frequencies of the RT wt and RT Y181C alleles found in Z6gpt + cell clones without NVP selection were 0?6 and 0?4, respectively, suggesting that, under no selective pressure, there is an equal distribution of integrated genomes. Next, the genetic composition of proviral DNA obtained from colonies selected with 0?2 mM NVP (a concentration higher than the EC 50 ; see Fig. 3 ) was analysed. Upon selection, we observed that RT Y181C alleles were integrated preferentially into host-cell genomes. In fact, under NVP selection, RT wt and RT Y181C allele frequencies were 0?32 and 0?68, respectively, when virus stocks were obtained from ratios of 1 : 1 co-transfection experiments (Fig. 4a) . Therefore, we found a consistent twofold increase in frequency of the resistant over the wild-type allele in the presence of NVP treatment. This difference was statistically significant and suggested that Gag-Pol incorporation into Gag/Gag-Pol complexes was specific with its cognate vRNA, as predicted by the in cis model. For experiments carried out with virus stocks obtained from co-transfection ratios of 5 : 1 (Fig. 4b) , the increased frequency found for the RT Y181C allele in the presence of NVP remained significant (0?45 for the resistant and 0?55 for the wild-type counterpart, compared with 0?18 for the resistant and 0?82 for the wild-type counterpart under no selection). Indeed, even departing from an excess of the wild-type virus present in the infectious stock, the increase in the resistant allele frequency under NVP treatment was statistically significant when compared with the previous situation in the absence of NVP treatment (Fig. 4b) , suggesting again that Gag-Pol molecules can interfere in the process of vRNA incorporation.
Measurement of vRNA incorporation directly into virus particles
Results obtained with integrated genomes after NVP selection suggest that Gag-Pol proteins were co-encapsulated with Gag multimers containing the former cognate vRNA into viable HIV particles. The nature of vRNA incorporation directly into intact virus particles using NERT was evaluated further. In this methodology, by adding an excess of dNTPs, the viral genomic RNA inside retrovirus particles is reversetranscribed to DNA by RT endogenous activity (Hooker & Harrich, 2003; Hooker et al., 2001) . As the amphipathic domains of the viral transmembrane protein gp41 render the viral outer coat permeable to a range of small molecules, including dNTPs, intravirion DNA synthesis will occur in the absence of permeabilizing agents (Zhang et al., 1996) . The first product of HIV-1 reverse transcription is a 181 nt fragment known as 2ssDNA.
A quantitative NERT real-time PCR assay that directly measured the effects of RT inhibitors on early reverse transcription in intact virions was created and the minimum NVP concentration required for selection of viruses harbouring RT Y181C -resistant molecules was determined (Fig. 5a) . For NERT experiments, we used the env + versions of each proviral clone (Z6gptRT Y181C and Z6gptRT wt ). Intact virions were exposed for 2 h to increasing concentrations of the drug prior to NERT reactions. Synthesis of 2ssDNA in wild-type viruses was inhibited with 10-50 mM NVP, whereas mutant Z6gptRT Y181C virus was resistant to NVP at concentrations up to 256 mM (Fig. 5b) . The inhibition profile of NVP in NERT reactions of 1 : 1 cotransfection experiments was similar to that found for integrated proviruses (Fig. 5b) . The NVP concentration sufficient to inhibit 50 % of the wild-type 2ssDNA synthesis (2 mM) was in agreement with previous studies that evaluated the effects of RT inhibitors during NERT clones were used to infect fresh COS-7 cells exposed or not to 0?2 mM NVP. At least 100 Z6gpt + COS-7 cell clones were isolated and expanded to recover genomic DNA from the cells. The HIV-1 RT genotype integrated into genomic DNA was analysed by sequencing of the RT region. The differences found for the RT genotype frequencies in infected COS-7 cells in the presence and absence of NVP were statistically significant for both 1 : 1 (P=0?0054) and 5 : 1 (P=0?0047) co-transfections, as calculated by the x 2 test. Schematic representation of the PCR strategy and primers used to detect NERT "ssDNA synthesis. The absolute quantification of NERT activity and inhibition by NVP were determined by using oligonucleotides SSF1, SSR1 and the single-stranded DNA (ssDNA) probe. The nature of vRNA incorporated into viruses was identified by PCR of the NERT products using D1 and P2-FAM followed by BamHI digestion, and the restriction fragments were analysed in an automated sequencer using GENESCAN fragment-analysis software. (b) Effect of NVP pretreatment on NERT activity of wild-type (Z6gptRT ) co-transfected viruses. Identical aliquots of virus were exposed to increasing concentrations of NVP 2 h prior to the NERT reaction and "ssDNA synthesis was measured by using a real-time PCR assay as described above. The absolute quantification of "ssDNA synthesis is represented as the percentage relative to the NERT positive control without NVP selection. The basal values of "ssDNA synthesis in negative controls were subtracted in all other results. (c) Proportion of resistant and wild-type "ssDNA fragments in 1 : 1 co-transfections of Z6gptRT Y181C and Z6gptRT wt viruses submitted to increasing NVP concentrations before the NERT reaction. All results were obtained from three independent experiments and are shown as means±SD. ). However, it should be noted that residual wild-type RT activity (around 20 %) could still be detected, even with concentrations of NVP as high as 256 mM.
NERT reactions were further used to identify directly the nature of genomic RNA within virions. NERT products were used to amplify by PCR a fragment encompassing the R-U5 region of the 59 LTR. Further BamHI digestion distinguished specifically between Z6gptRT Y181C genomic RNA and the Z6gptRT wt counterpart (Figs 1, 5a ). Fragments were separated after restriction digestion through sequencing electrophoresis and GENESCAN software was used for analysis of the length and area of each fragment (RFLP). The ratio of digested and non-digested fragments obtained from NERT reactions from 1 : 1 virus with or without NVP selection was representative of the ratio of Z6gptRT wt and Z6gptRT
Y181C virion-incorporated genomes. Likewise, for integrated HIV genomes, the prevalence of the Z6gptRT Y181C genome in the NERT reactions in the presence of NVP demonstrated an intimate association between mutant RT and its cognate vRNA, increasing the efficiency of mutant vRNA reverse transcription both in homodimers of mutants and in heterodimers. Our results demonstrated that, in the absence of NVP, the frequency of Z6gptRT Y181C vRNA was slightly lower than its wild-type counterpart (Z6gptRT Y181C /Z6gptRT wt =0?8) (Fig. 5c ). However, following NVP selection, the frequency of Z6gptRT Y181C increased over the frequency of the Z6gptRT wt genome proportionally with the increase in drug concentration, and a twofold higher frequency of the resistant vRNA was observed for the highest NVP concentration used (Fig. 5c) . These results confirmed that the incorporation of vRNA and Gag-Pol molecules into virus particles is specific and suggest that Gag-Pol itself could help in coordinating genome incorporation during viral assembly.
DISCUSSION
In this work, we demonstrated that Gag-Pol molecules possessing a drug-resistant mutation are incorporated specifically into virus particles carrying their cognate vRNA. Our results suggested that Gag-Pol molecules may influence the type of vRNA selected for incorporation during viral assembly in a strong selective pressure environment. The system described here is based on genetic analyses of incorporated proviral DNA obtained from MPA-selected single infected-cell colonies after an abortive infection process. In this way, the proviral DNA found in each surviving colony is representative of the former genomic RNA present in the virion able to infect that colony. As viral stocks were obtained from cells co-expressing equal amounts of wild-type and resistant HIV-1 genomes differing only in their capacity to respond to NVP treatment, following NVP selection, an increase in the frequency of the resistant proviral genome compared with the wild-type proviral genome would indicate a preferential incorporation of the former. The same holds for analyses performed directly in virus particles by NERT assays. Our results demonstrated a twofold increase in resistant genomic RNA frequencies over the wild-type counterpart after drug selection, both in cells harbouring integrated proviruses selected after one round of infection and directly in vRNA present in virions.
In our system, heterozygous virions were obtained from cells co-transfected with two distinct proviral DNAs in equal proportions. Despite the excess of virus produced in this cell system, this is in close proximity to in vivo observations, as splenocytes from HIV-1-infected individuals demonstrate a high number of integrated proviruses per infected cell (Dang et al., 2004) . Furthermore, double infections occur frequently in infected cultures of primary and established CD4 + cells, providing the basis for the generation of heterozygous virions (Jung et al., 2002) .
Genomic RNA incorporation is a highly specific event during viral assembly and cis-acting sequences within this genomic RNA are essential for its preferential selection over the many other mRNA species present in the cell cytoplasm during assembly. Gag is responsible for interacting with such sequences and specifically selects full-length, non-spliced viral mRNA for incorporation. For HIV-2, a model for genomic RNA incorporation by in cis packaging has been proposed in which unspliced RNA is sequestered by its cognate newly synthesized Gag (Kaye & Lever, 1999) . This is necessary and essential for vRNA selection, because the packaging signal of HIV-2 is upstream of the major splice donor and thus exists on both spliced and unspliced RNA species. Controversy exists, however, regarding the initiation mechanism for HIV-1 genomic RNA incorporation. In fact, several studies have demonstrated that HIV-1 Gag incorporates unspliced genomic RNA efficiently both in trans and in cis. However, studies demonstrating that the HIV-1 unspliced mRNA pool can function interchangeably as genomic RNA and as template for Gag and Gag-Pol translation were performed in conditions in which no competition between two distinct RNA species existed (Butsch & Boris-Lawrie, 2000; Griffin et al., 2001; McBride et al., 1997) . However, when different unspliced RNA species are present at the same time during viral assembly, it has been demonstrated that the nascent Gag proteins specifically incorporate their cognate RNA (Liang et al., 2002; Poon et al., 2002) . Swanson et al. (2004) demonstrated that the Gag-Pol mRNA export pathways determine the sites of protein translation in the cytoplasm of infected cells influencing the efficiency of virion assembly. These findings agree with the facts that Gag and vRNA interaction occurs at a perinuclear site very early during viral assembly, that it facilitates Gag multimerization and that it helps the assembly complex to migrate to sites of viral budding (Poole et al., 2005 , and references therein). Thus, although there is an interchangeable use of HIV-1 unspliced mRNA for both encapsulation and translation, upon specific selective pressure, a preference for cis packaging can be observed. This corroborates well with our results, in which, following NVP selection, mutant Z6gptRT Y181C genomic RNA was packaged at a twofold-higher level than the wild-type Z6gptRT wt , given equal expression of both RNAs in co-transfected cells. Our results suggest that, as for Gag, newly synthesized Gag-Pol proteins could establish interactions with Gag multimers very early during translation and, at the same time, with their cognate mRNA that served as template, and this entire complex would be directed efficiently for budding. We observed a significant shift in RT allelic frequencies following NVP selection either in 1 : 1 or 5 : 1 (Z6gptRT wt : Z6gptRT
Y181C
) cotransfection ratios, for both gpt + clones (Fig. 4a and b ) and newly synthesized 2ssDNA in NERT reactions (Fig. 5c ). Both integrated proviruses and cell-free virions favoured the specific in cis model for vRNA incorporation.
The increase in the proportion of RT Y181C compared with RT wt vRNA following NVP selection observed by NERT was slightly lower than that observed for genome integration in transduced cells. This could be due to a significant level of incorporation of single-spliced subgenomic RNA into new virions, as demonstrated previously (Liang et al., 2004) . Moreover, the residual activity of wild-type RT, even in the presence of high concentrations of NVP, could also account for the lower frequency of the mutant 2ssDNA, as the wildtype counterpart would still be synthesized by its wild-type RT.
Gag molecules are the major components driving genomic RNA incorporation through interaction between the nucleocapsid domain in Gag and the Y site within unspliced RNA. Although such interaction is essential for RNA recruitment, it is not sufficient, and additional viral and/or cellular factors seem to play a role in this process (Aldovini & Young, 1990) . In fact, interactions between unspliced genomic RNA and the RT region in the unprocessed Gag-Pol have already been demonstrated and seem to be important for holding Pol components in virions during viral maturation (Cen et al., 2004) . Taken together, these results may imply that Gag-Pol molecules also play an important role during RNA packaging, suggesting that, as for Gag, Gag-Pol proteins to a lesser extent can select genomic RNA for incorporation. Importantly, in our system, the observed twofold increase in the levels of resistant Z6gptRT Y181C genomic RNA incorporation compared with the susceptible Z6gptRT wt could be explained by the lesser contribution of Gag-Pol to this process. This could be explained by the 20 : 1 ratio of Gag to Gag-Pol proteins present in virions (Jacks et al., 1988) . Even considering that Gag-Pol will seldom select its own template as the viral genome, Gag-Pol polyproteins harbouring resistant mutations in the RT gene will selectively pass the resistant genome on to the next infected cell in a selective environment, such as in the presence of anti-RT drugs, demonstrating the importance of this event.
In vitro assembly analyses have shown that viral RNA might function as a scaffold for the multimerization of viral precursor proteins (Khorchid et al., 2002) . Furthermore, packaging of the mature dimeric RNA genome is dependent on pol products (Shehu-Xhilaga et al., 2001, 2002 ). These findings are in agreement with a model in which Gag-Pol also plays an important role for the incorporation of vRNA, suggesting that vRNA interaction with Gag-Pol occurs prior to RNA dimerization.
Together, these results support a cis packaging model in which nascent Gag-Pol proteins are preferentially coencapsulated with Gag multimers and their cognate RNA into HIV particles, especially in a scenario in which two distinct unspliced genomic RNAs co-exist. This model links translation, packaging and the assembly process, placing Gag-Pol and vRNA components in close proximity where they can interact. This model could also have implications for selecting virions carrying resistant proteins and genomes inside the same particle, thus increasing the likelihood of resistant virus expansion if exposed to anti-retroviral drug selection.
